Antibodies & Complement

May 20-25, 2019





Antibodies & Complement

May 20-25, 2019

Speakers

Doryen Bubeck, Imperial College, London (United Kingdom)

Christian Busse, German Cancer Research Center, Heidelberg (Germany)

Tineke Cantaert, Institut Pasteur, Phnom Penh (Cambodia)

Michael Carroll, Harvard Medical School, Massachusetts (USA)

Michel Cogné, University of Limoges (France)

Davide Corti, Humabs BioMed SA, Bellinzona (Switzerland)

Brandon de Kosky, University of Kansas (USA) Sarel J. Fleishman, Weizmann Institute, Rehovot (Israel)

Piet Gros, Utrecht University (The Netherlands)

Claudia Kemper, National Insitute of Health, Bethesda (USA)

Florian Krammer, Icahn School of Medicine at Mount Sinai, New York (USA)

Heidi Ling, Imperial College, London (United Kingdom)

Brinda Prasad, Regeneron Pharmaceuticals, New York (USA)

Daniel Ricklin, University Basel (Switzerland)

Janine Schuurman, Genmab Utrecht (The Netherlands)

Ron Taylor, University of Virginia (USA)

Franscesco Tedesco, University of Trieste (Italy)

Marjolein van Egmond, VU University Medical Center (The Netherlands)

Andrea van Elsas, Aduro Biotech Europe, Oss (The Netherlands)

Taia Wang, Stanford University, California (USA)

TOPICS

- · antibody & complement (novel) functions
- · human antibody repertoires
- · complement structure and subcellular localization
- novel technologies
- complement and antibody therapies

Scientific Organizers

Pierre Bruhns

Institut Pasteur, Paris, France

Falk Nimmerjahn

University of Erlangen-Nuernberg, Germany

Suzan H.M. Rooijakkers

University Medical Center Utrecht, The Netherlands

Kathrin de la Rosa

Max Delbrück Center for Molecular

Medicine in the Helmholtz Association Berlin, Germany

Program

Monday, May 20, 2019

14:00	Registration
16:30	Welcome & Introductions by Pierre Bruhns and Kathrin de la Rosa
Antibod	ies & Complement I
Chairs:	Pierre Bruhns, Institut Pasteur, Paris, France Kathrin de la Rosa, Max Delbrück Center for Molecular Medicine, Berlin, Germany
16:40	Michael Carroll, Harvard Medical School, Massachusetts, USA Complement in adaptive immunity
17:20	Selected abstract: Christian Lehmann, University Hospital Erlangen, Germany Antigen targeting of Fc receptors induces strong and functional relevant T cell responses in vivo independent of ITAM signaling but dependent on dendritic cell subsets
17:40	Selected abstract: Kasia Kready, Institut Pasteur, Paris, France Tracking Temporal and Spatial Affinity Maturation of Antibodies from Single-Cells in a mouse model of autoimmunity
17:55	Selected abstract: Steven de Taeye, Sanquin, Amsterdam, The Netherlands Polymorphic variant of IgG2 is less efficient in complement activation
18:10	Brinda Prasad, Regeneron Pharmaceuticals, New York, USA Enhancing Pathogen and Cellular Clearance with a Bispecific C1q Antibody
19:00	Welcome Reception – Networking
20:00	Dinner

Antibodies & Complement II Chairs: Suzan Rooijakkers, University Medical Center Utrecht, The Netherlands Falk Nimmeriahn. FAU Erlangen-Nuremberg. Germany

- 09:00 Janine Schuurman, Genmab, Utrecht, The Netherlands Translating basic science to antibody therapeutics
- 09:40 Selected abstract: Jürgen Strasser, University of Applied Sciences Upper Austria, Linz, Austria The molecular pathways of IgG oligomerization and classical complement activation on antigenic surfaces
- 10:00 Selected abstract: Ben Goldberg, Dartmouth College, Hanover, USA Squaring in vitro complement assays with in vivo results: case studies in anti-HIV-1 complement activity
- 10:15 Selected abstract: Seline Zwarthoff, UMC, Utrecht, The Netherlands Proteases C1r and C1s affect binding of C1q to certain human IgG subclasses
- 10:30 Coffee break
- 11:00 Heidi Ling, Imperial College, London, UK Complement in autoimmune diseases
- 11:40 Selected abstract: Eva Conde Garcia, Institut Pasteur, Paris, France Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic airway inflammation in mice
- 12:00 Selected abstract: Cécile Bergua, IRIB Normandy, Rouen, France
 In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in
 immune-mediated necrotising myopathy
- 12:15 Selected abstract: Pablo Canales Herrerias, Institut Pasteur, Paris, France Characterizing autoantibody-producing cells in thrombocytopenic patients for secretion rate and affinity for a platelet autoantigen
- 12:30 Lunch and social time

Chairs:	Pierre Bruhns, Institut Pasteur, Paris, France Janine Schuurman, Genmab, Utrecht, The Netherlands
15:00	Ron Taylor, University of Virginia, USA The mechanism of antibody-induced complement-mediated lysis of tumor cells
15:40	Selected abstract: Haoyang Zhuang, University of Florida, USA A Novel Mechanism for Generating the Interferon Signature in Lupus: Opsonization of Dead Cells by Complement and IgM
15:55	Selected abstract: Simone Oostindie, Genmab, Utrecht, The Netherlands DuoHexaBody-CD37: a novel CD37-specific antibody that demonstrates superior complement-dependent cytotoxicity in pre-clinical B-cell malignancy models
16:10	Marjolein van Egmond, VU University Medical Center Amsterdam, The Netherlands IgA therapeutic antibodies
16:50	Selected abstract: Sina Bondza, Uppsala University, Sweden Characterization of Rituximab and C1q interactions on living cells in real-time
17:05	Selected abstract: Delphine Sterlin, Institut Pasteur, Paris, France Human IgA coat a wide range of gut commensals
17:30	Poster Session I (P1-P28)
20:00	Dinner

Antibodies in infectious diseases

Chairs:	Kathrin de la Rosa, Max Delbrück Center for Molecular Medicine, Berlin, Germany Bart Bardoel, University Medical Center Utrecht, The Netherlands
09:00	Davide Corti, VIR, Bellinzona, Switzerland Novel therapeutic antibodies in infectious diseases
09:40	Selected abstract: Leire Aguinagalde, UMC, Utrecht, The Netherlands Complement-enhancing monoclonal antibodies as a therapeutic strategy against Streptococcus pneumoniae
10:00	Selected abstract: Elizabeth Aitken, University of Melbourne, Australia Identifying functional antibodies that protect pregnant women against placental malaria infection
10:15	Selected abstract: Harry Schroeder, University of Alabama at Birmingham, USA Pneumococcal vaccination elicits public B-cell repertoires and serum antibody clonotypes derived from the IgM+IgD+CD27+ memory B cell compartment
10:30	Coffee break
11:00	Tineke Cantaert, Institut Pasteur, Phnom Penh, Cambodia Protective antibody response in dengue infections
11:40	Selected abstract: Timothée Bruel, Institut Pasteur, Paris, France Complement activation at the surface of HIV-1-infected cells
12:00	Selected abstract: Priscilla Kerkman, UMC, Utrecht, The Netherlands Extracellular ATP can mediate cleavage of CD27 to generate CD27-lgD- B cells in circulation of hantavirus patients.
12:15	Florian Krammer, Icahn School of Medicine at Mount Sinai, New York, USA Antibody responses to conserved influenza virus epitopes
12:55	
12.55	Lunch and social time

Chairs:	Falk Nimmerjahn, FAU Erlangen-Nuremberg, Germany Florian Krammer, Icahn School of Medicine at Mount Sinai, New York, USA
18:00	Christian Busse, German Cancer Research Center, Heidelberg, Germany Anti-malaria Abs and repertoires analysis
18:40	Selected abstract: Peter Rice, UMASS, Massachusetts, USA Complement alone drives efficacy of a chimeric anti-gonococcal monoclonal antibody
19:00	Selected abstract: Timon Damelang, University of Melbourne, Australia Importance of functional antibodies in protection of pregnant women from malaria
19:15	Taia Wang, Stanford University, USA Fucosylation on anti-dengue antibodies
20:00	Dinner

Complement

Chairs:	Suzan Rooijakkers, University Medical Center Utrecht, The Netherlands Doryen Bubeck, Imperial College, London, UK
09:00	Piet Gros, Utrecht University, The Netherlands Antibody and complement structures
09:40	Selected abstract: Ravit Netzer, Weizmann Institute of Science, Rehovot, Israel Automated design of ultrahigh specificity protein binders
10:00	Selected abstract: Rolf Spirig, CSL Behring AG, Bern, Switzerland Inhibition of Ab-complex mediated inflammation by recombinant IgG1 Fc hexamer
10:15	Selected abstract: Dennis Doorduijn, UMC, Utrecht, The Netherlands Bacterial killing by MAC pores requires immediate assembly of C5b-7
10:30	Coffee break
11:00	Daniel Ricklin, University Basel, Switzerland The Renaissance of Complement Therapeutics: Taming a Host Defense Pathway Gone Astray
11:40	Selected abstract: Alex Macpherson, UCB Pharma, Slough, UK A VHH-assisted study of the C5 inhibitory mechanisms of OmCl and RaCl
11:55	Selected abstract: Immaculada Margarit Y Ros, GSK Vaccines, Siena, Italy The Streptococcus agalactiae CIP Complement Inhibitory Protein at the interface between innate and acquired immunity
12:10	Selected abstract: Dani Heesterbeek, UMC, Utrecht, The Netherlands Disruption of Gram-negative bacteria by human serum requires complement and lysozyme
12:25	Lunch and social time

Chairs:	Pierre Bruhns, Institut Pasteur, Paris, France Daniel Ricklin, University Basel, Switzerland
15:00	Doryen Bubeck, Imperial College, London, UK Cryo-EM structures of MAC
15:40	Claudia Kemper, National Institutes of Health, Bethesda, USA Unexpected roles for the complosome in cell metabolism
16:20	Michel Cogné, University of Limoges, France IgG5, the new human IgG subclass
17:30	Poster Session II (P29-P56)
20:00	Dinner

Antibody features

Chairs:	Kathrin de la Rosa, Max Delbrück Center for Molecular Medicine, Berlin, Germany David Humphreys, UCB Pharma, Slough, UK
09:00	Sarel J. Fleishman, Weizmann Institute, Israel Computational design of antibodies
09:40	Selected abstract: Jordan Dimitrov, INSERM, Paris, France Eccentric associations: interaction of antibodies with cofactors
10:00	Selected abstract: Mikhail Lebedin, MDC, Belin, Germany Antibody diversification through non-VDJ insertions
10:15	Selected abstract: Christin Brueckner, FAU Erlangen-Nuremberg, Germany Investigating the mechanisms of IVIg mediated resolution of autoimmune inflammation
10:30	Coffee break
11:00	Andrea van Elsas, Aduro Biotech Europe, Oss, The Netherlands Cancer immunotherapy beyond PD1: novel immunomodulatory antibodies
11:40	Selected abstract: Aaron Meyer, UCLA, USA A Multivalent Binding Model Predicts FcyR Regulation and Effector Cell-Elicited Killing
12:00	Brandon de Kosky, Kansas University Interpreting antibody sequence and function on a repertoire scale
12:40	Lunch and social time

Chairs:	Suzan Rooijakkers, University Medical Center Utrecht, The Netherlands Falk Nimmerjahn, FAU Erlangen-Nuremberg, Germany
18:00	David Humphreys, UCB Pharma, Slough, UK Studies with Fc-multimers: hexameric Fc and on-target hexameric IgG
18:40	Selected abstract: Simone Mader, LMU, Munich, Germany In utero exposure to anti-Aquaporin-4 antibodies alters brain vasculature und results in dys- function of spatial cognitive function
19:10	Francesco Tedesco, Istituto Auxologico Italiano, Milan, Italy Alternative roles of C1q in cancer and tissue remodeling
20:00	Dinner
22:00	Social entertainment



SUPPORTED BY







ANTI BODY SOCI . ETY











